DONALD SMITH: Open Payments
NPI 1952388035 · RICHMOND, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$731 in 33 payments from 17 companies in 2025. Trend: 2023 $429 · 2024 $548 · 2025 $731
Food & beverage: $681Long term medical supply or device loan: $50
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $154 |
| Eisai Inc. | 3 | $111 |
| Abbott Laboratories | 3 | $78 |
| Lilly USA, LLC | 3 | $55 |
| Teva Pharmaceuticals USA, Inc. | 2 | $53 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| JAZZ PHARMACEUTICALS INC. | 1 | $38 |
| PFIZER INC. | 2 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Smith+Nephew, Inc. | 1 | $22 |
Products named: CAPLYTA, Leqembi, AUSTEDO XR, FANAPT, FREESTYLE INSULINX, MOUNJARO, XYWAV, FREESTYLE LIBRE 3.
Industry payments across IN — which companies pay providers there.
